Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3450128 | 0.98 | ALDH1A1 (0.96) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL30189955 | 0.98 | ALDH1A1 (0.96) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL691842 | 0.96 | ALDH1A1 (0.92) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL13125941 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL13125914 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL6862670 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL167247 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL2035154 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL2691499 | 0.74 | ALDH1A1 (0.59) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL12938269 | 0.74 | ALDH1A1 (0.59) | ALDH1A1MAPK1SMN1; SMN2APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-4223750-B1 | NITROGEN-CONTAINING BICYCLIC COMPOUNDS WHICH CONTAIN PYRIMIDINE AS INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK-4) INHIBITORS TO BE USED IN THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES | ASAHI KASEI PHARMA CORP (JP) | 2025-06-25 | — | — | EP | disclosed |
| CN-116194454-B | Pyrimidine-containing nitrogen-containing bicyclic compounds | 旭化成制药株式会社 | 2025-02-18 | — | — | CN | disclosed |
| CN-117946098-A | Pyrimidine PLK1 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116194454-A | Pyrimidine-containing nitrogen-containing bicyclic compounds | 旭化成制药株式会社 | 2023-05-30 | — | — | CN | disclosed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| EP-0843681-B1 | HETEROCYCLE-FUSED THIAZOLE DERIVATIVES | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
| US-6043373-A | ANTIULCER AGENT | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-03-28 | — | — | US | disclosed |
| EP-0843681-A1 | HETEROCYCLE-FUSED THIAZOLE DERIVATIVES | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997003076-A1 | HETEROCYCLE-FUSED THIAZOLE DERIVATIVES | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | ALDH1A1 3860/4885MAPK1 3934/4885SMN1; SMN2 1222/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | ALDH1A1 3860/4885MAPK1 3934/4885SMN1; SMN2 1222/4885 |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | ALDH1A1 2898/4885MAPK1 128/4885SMN1; SMN2 1514/4885 |
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | ALDH1A1 712/4885MAPK1 149/4885SMN1; SMN2 4285/4885 |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | IRAK1, IRAK4, IRAK2 | ALDH1A1 3202/4885MAPK1 152/4885SMN1; SMN2 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.